(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

How do we know which patients truly need this difficult treatment and which patients can safely skip it? The answer has arrived, delivered at the American Society for Radiation Oncology (ASTRO) 2025 ...

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center One hundred twenty-two participants completed the survey. The majority ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...

Decipher Prostate Metastatic Genomic Classifier has been launched for use in patients whose prostate cancer has spread beyond the primary tumor, according to a news release from Veracyte, Inc. The ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Memorial Medical Center in Las Cruces is introducing a new genetic testing tool that can identify gene mutations passed down through families that ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...